No Data
Sector Update: Health Care
Health care stocks were higher late Tuesday afternoon, with the NYSE Health Care Index adding 0.5% and the Health Care Select Sector SPDR Fund (XLV) up 0.3%. The iShares Biotechnology ETF (IBB) rose 0
Ascendis Pharma Says FDA Has Delayed TransCon PTH Review
Ascendis Pharma Says FDA Extending Review Period for NDA
By Ben Glickman Ascendis Pharma said regulators had pushed back the target action date for reviewing its hypoparathyroidism treatment after the company submitted additional information. The Danish b
UPDATE 1-FDA Extends Review of Ascendis Pharma's Hormone Disorder Therapy
Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon PTH for Adults With Hypoparathyroidism
- Prescription Drug User Fee Act (PDUFA) goal date extended by three months for further review of submission to August 14, 2024 COPENHAGEN, Denmark, May 14, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND)
Ascendis Pharma Announces 2-Year Results From A Post-hoc Analysis Of Their Phase 3 Pathway Trial Demonstrating Sustained Improvements In Renal Function In Adults With Chronic Hypoparathyroidism Treated With TransCon PTH
Ascendis Pharma A/S (NASDAQ:ASND) today announced 2-year results from a post-hoc analysis of the Company's Phase 3 PaTHway Trial demonstrating significant and sustained improvements in renal function
baqklin : thanks
74349332 : what site do you get this informatiom from?